Analyst Patrick B Donnelly from Citi maintained a Hold rating on Thermo Fisher and increased the price target to $580.00 from $500.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Patrick B Donnelly has given his Hold rating due to a combination of factors impacting Thermo Fisher’s financial outlook. The company has shown positive developments in its third-quarter results, with increases in revenue, operating profit margin, and earnings per share. However, the organic growth rate remains modest at around 2%, and the company anticipates challenges in the fourth quarter due to government shutdown impacts and a decline in AI-related growth.
Despite the positive adjustments to the financial targets for 2025, including a raised revenue forecast and improved operating margins, there are concerns about headwinds such as COVID-related sales runoff and tariff impacts. Additionally, recent acquisitions, while contributing to revenue, are expected to be slightly dilutive to earnings per share in the short term. These mixed signals, along with the company’s reiterated medium-term growth targets, have led to the decision to maintain a Neutral stance with a slight increase in the target price.
B Donnelly covers the Healthcare sector, focusing on stocks such as Mettler-Toledo, Exact Sciences, and Icon. According to TipRanks, B Donnelly has an average return of 2.7% and a 50.99% success rate on recommended stocks.